A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline
Alam et al.,
A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline,
Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 (Preprint)
Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported.
Alam et al., 31 Jul 2020, preprint, 4 authors.
Abstract: ORIGINAL ARTICLE
European Journal of Medical and Health Sciences
www.ejmed.org
Ivermectin as Pre-exposure Prophylaxis for COVID-19
among Healthcare Providers in a Selected Tertiary
Hospital in Dhaka – An Observational Study
Mohammed Tarek Alam, Rubaiul Murshed, Pauline Francisca Gomes, Zafor Md. Masud, Sadia Saber,
Mainul Alam Chaklader, Fatema Khanam, Monower Hossain, Abdul Basit Ibne Momen, Naz Yasmin,
Rafa Faaria Alam, Amrin Sultana, and Rishad Choudhury Robin
ABSTRACT
Introduction: While multiple vaccines are undergoing clinical trial across
the globe, we yearn for an FDA approved drug to protect us from the
devastating pandemic for the time being. This study aims to determine the
effectiveness of Ivermectin when administered as pre-exposure prophylaxis
for COVID-19.
Method: An observational study, with 118 healthcare providers who were
enrolled purposively, was conducted in a tertiary hospital in Dhaka from
May 2020 to August 2020. The subjects were divided into experimental and
control groups; and the experimental group received an oral monthly dose
of Ivermectin 12mg for 4 months. Both groups were exposed to COVID-19
positive patients admitted in the hospital during the course of study. The
symptomatic subjects were evaluated by physical examination, COVID-19
RT-PCR and/or HRCT of chest. Differences between the variables were
determined using the Chi-square test and the level of statistical significance
was reached when p<0.05.
Result: 73.3% (44 out of 60) subjects in control group were positive for
COVID-19, whereas only 6.9% (4 out of 58) of the experimental group
were diagnosed with COVID-19 (p-value < 0.05).
Conclusion: Ivermectin, an FDA-approved, safe, cheap and widely
available drug, should be subjected to large-scale trials all over the world to
ascertain its effectiveness as pre-exposure prophylaxis for COVID-19.
Keywords: COVID-19, Ivermectin, Prophylaxis, Healthcare worker,
Bangladesh.
Published Online: December 15, 2020
ISSN: 2593-8339
DOI: 10.24018/ejmed.2020.2.6.599
Mohammed Tarek Alam*
Bangladesh Medical College Hospital,
Shomman Foundation, Bangladesh.
(e-mail: mtarekalam16@gmail.com)
Rubaiul Murshed
Shomman Foundation, Bangladesh.
Pauline Francisca Gomes
Shomman Foundation, Bangladesh.
Zafor Md. Masud
Bangladesh Medical College Hospital,
Shomman Foundation, Bangladesh.
Sadia Saber
Bangladesh Medical College Hospital,
Bangladesh.
Mainul Alam Chaklader
Bangladesh Medical College Hospital,
Bangladesh.
Fatema Khanam
Bangladesh Medical College Hospital,
Bangladesh.
Monower Hossain
Bangladesh Medical College Hospital,
Bangladesh.
Abdul Basit Ibne Momen
Bangladesh Medical College Hospital,
Shomman Foundation, Bangladesh.
Naz Yasmin
International
Medical
College,
Bangladesh.
Rafa Faaria Alam
Bangladesh Medical College Hospital,
Shomman Foundation, Bangladesh.
Amrin Sultana
Bangladesh Medical College Hospital,
Bangladesh.
Rishad Choudhury Robin
Shomman Foundation, Bangladesh.
*Corresponding Author
I. BACKGROUND
Submerged in the wave of Coronavirus disease 2019
(COVID-19), the world is weeping. Ever since the outbreak
was first identified in December 2019 in Wuhan, China the
world has not been the same [1]. An ongoing pandemic, the
DOI: http://dx.doi.org/10.24018/ejmed.2020.2.6.599
COVID-19 has proved to be the most devastating and
unmanageable crisis the world has ever encountered. With
the virus proudly lurking around in the atmosphere, millions
of lives have already been compromised and many more
uncountable..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit